206 related articles for article (PubMed ID: 6773632)
21. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro.
Carano A; Teitelbaum SL; Konsek JD; Schlesinger PH; Blair HC
J Clin Invest; 1990 Feb; 85(2):456-61. PubMed ID: 2105340
[TBL] [Abstract][Full Text] [Related]
22. The anabolic action of 17 beta-estradiol (E2) on rat trabecular bone is suppressed by (3-amino-1-hydroxypropylidene)-1-bisphosphonate (AHPrBP).
Abe T; Chow JW; Lean JM; Chambers TJ
Bone Miner; 1992 Oct; 19(1):21-9. PubMed ID: 1422303
[TBL] [Abstract][Full Text] [Related]
23. Parenteral pamidronate prevents thyroid hormone-induced bone loss in rats.
Rosen HN; Sullivan EK; Middlebrooks VL; Zeind AJ; Gundberg C; Dresner-Pollak R; Maitland LA; Hock JM; Moses AC; Greenspan SL
J Bone Miner Res; 1993 Oct; 8(10):1255-61. PubMed ID: 8256663
[TBL] [Abstract][Full Text] [Related]
24. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
[TBL] [Abstract][Full Text] [Related]
25. Effects of hypervitaminosis A on the bone and mineral metabolism of the rat.
Hough S; Avioli LV; Muir H; Gelderblom D; Jenkins G; Kurasi H; Slatopolsky E; Bergfeld MA; Teitelbaum SL
Endocrinology; 1988 Jun; 122(6):2933-9. PubMed ID: 3371268
[TBL] [Abstract][Full Text] [Related]
26. Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD), in rats and mice.
Cal JC; Daley-Yates PT
Toxicology; 1990 Dec; 65(1-2):179-97. PubMed ID: 1980383
[TBL] [Abstract][Full Text] [Related]
27. Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo.
van der Pluijm G; Binderup L; Bramm E; van der Wee-Pals L; De Groot H; Binderup E; Löwik C; Papapoulos S
J Bone Miner Res; 1992 Aug; 7(8):981-6. PubMed ID: 1442212
[TBL] [Abstract][Full Text] [Related]
28. Changes in bone mineralization, architecture and mechanical properties due to long-term (1 year) administration of pamidronate (APD) to adult dogs.
Grynpas MD; Acito A; Dimitriu M; Mertz BP; Very JM
Osteoporos Int; 1992 Mar; 2(2):74-81. PubMed ID: 1536983
[TBL] [Abstract][Full Text] [Related]
29. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure.
Lomashvili KA; Monier-Faugere MC; Wang X; Malluche HH; O'Neill WC
Kidney Int; 2009 Mar; 75(6):617-25. PubMed ID: 19129793
[TBL] [Abstract][Full Text] [Related]
30. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
Coleman RE; Rubens RD
Br J Cancer; 1987 Oct; 56(4):465-9. PubMed ID: 3689664
[TBL] [Abstract][Full Text] [Related]
31. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp PM; van der Wee-Pals LJ; van Wijk-van Lennep MM; Thesing CW; Bijvoet OL
Bone Miner; 1986 Feb; 1(1):27-39. PubMed ID: 3508715
[TBL] [Abstract][Full Text] [Related]
32. Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats.
Kostenuik PJ; Orr FW; Suyama K; Singh G
Cancer Res; 1993 Nov; 53(22):5452-7. PubMed ID: 8221685
[TBL] [Abstract][Full Text] [Related]
33. Bone resorption in orthotopic and heterotopic bone of dichloromethylene bisphosphonate-treated rats.
Nilsson OS; Bauer HC; Brosjö O; Törnkvist H
J Orthop Res; 1990 Mar; 8(2):213-9. PubMed ID: 2137534
[TBL] [Abstract][Full Text] [Related]
34. The influence of two diphosphonates on calcium metabolism in the rat.
Gasser AB; Morgan DB; Fleisch HA; Richelle LJ
Clin Sci; 1972 Jul; 43(1):31-45. PubMed ID: 5040757
[No Abstract] [Full Text] [Related]
35. Measurement of serum [3H]tetracycline kinetics and indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorption.
Golomb G; Eitan Y; Hoffman A
Pharm Res; 1992 Aug; 9(8):1018-23. PubMed ID: 1409371
[TBL] [Abstract][Full Text] [Related]
36. Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD).
Stone MD; Hawthorne AB; Kerr D; Webster G; Hosking DJ
J Bone Miner Res; 1990 Dec; 5(12):1231-5. PubMed ID: 2075835
[TBL] [Abstract][Full Text] [Related]
37. Effective oral treatment of severe Paget's disease of bone with APD (3-amino-1-hydroxypropylidene-1,1-bisphosphonate); a comparison with combined calcitonin + EHDP (1-hydroxyethylidene-1,1-bisphosphonate).
Fraser TR; Ibbertson HK; Holdaway IM; Rutland M; King A; Dodd G; Wattie DJ
Aust N Z J Med; 1984 Dec; 14(6):811-8. PubMed ID: 6442563
[TBL] [Abstract][Full Text] [Related]
38. Metabolic effects of pamidronate in patients with metastatic bone disease.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
Br J Cancer; 1996 May; 73(9):1089-95. PubMed ID: 8624269
[TBL] [Abstract][Full Text] [Related]
39. Pamidronate corrects the down-regulation of the renal parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor mRNA in rats bearing Walker tumors.
Yaghoobian J; Morieux C; Denne MA; Bouizar Z; Ureña P; de Vernejoul MC
Horm Metab Res; 1998 May; 30(5):249-55. PubMed ID: 9660083
[TBL] [Abstract][Full Text] [Related]
40. Effect of halogenmethylenebisphosphonates on bone cells in culture and on bone resorption in vivo.
Felix R; Fleisch H; Schenk R
Experientia; 1986 Mar; 42(3):302-4. PubMed ID: 3956686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
